Dobutamine and dopamine offer distinct hemodynamic profiles in cardiogenic shock, with dobutamine preferred for inotropic support that unloads the left ventricle, while dopamine or combination therapy is useful when blood pressure maintenance is required.
Answers are grounded in this paper and cite their sources.
May guide inotrope selection by hemodynamic targets in shock; leaves open need for RCTs on clinical outcomes.
The pharmacological therapy of cardiogenic shock is determined by the underlying pathophysiology. In pump failure, secondary to severe obstructive coronary artery disease with a large compartment of ischemic myocardium at risk, coronary reserve is severely impaired. Any attempt to improve cardiac performance must consider the delicate balance between oxygen supply and requirement. Coronary blood flow is dependent on coronary perfusion pressure. Agents increasing arterial blood pressure improve coronary perfusion, but do not increase cardiac output and, thus, interfere with perfusion of vital organs. Inotropic agents, improving cardiac performance, may increase myocardial oxygen requirements in excess of availability; improvement of peripheral perfusion occurs at cost of a deteriorating pump. Contrarily, in pump failure due to primary myocardial impairment, as myocardiopathy or depression of ventricular function by extracorporal circulation, impairment of energy utilization by the myocardium, of contractility, and of neuro‐humoral responses are primary factors. Measures to improve cardiac performance are less limited by considerations of increasing myocardial oxygen requirements. Dobutamine, a relatively selective beta1, agonist, and dopamine, a nonselective beta, alpha, and dopaminergic agonist, are the most frequently applied vasoactive agents in the treatment of cardiogenic shock. Their effects are highly dose dependent. Both catecholamines improve cardiac performance and peripheral perfusion. The major differences between the two drugs are related to the effect on heart rate, cardiac filling pressure, and systemic vascular resistance. At clinically tolerated doses, dobutamine is a more potent inotropic agent than dopamine. The decrease in vascular resistance, unloading the left ventricle, is beneficial for the failing heart. Heart rate remains essentially unchanged. In contrast, dopamine increases arterial pressure, left ventricular filling pressure and, at higher doses, heart rate. If blood pressure cannot be maintained by dobutamine, dopamine is preferable. Moreover, the combination of both vasoactive agents has been proven beneficial, supplemented by I‐norepinephrine, if necessary. An aggressive approach to unstable angina and complicated myocardial infarction, identification of the patient at high risk for sudden cardiac events, introduction of myocardial preservations during surgery, and improved techniques have contributed to the decreased frequency of cardiogenic shock.
No takes yet. Share an insight, caveat, or question.
Hiltrud S. Mueller (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: